These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6236877)

  • 1. In vitro functions of lymphocytes during high-dose medroxyprogesterone acetate (MPA) treatment.
    Grönroos M; Eskola J
    Cancer Immunol Immunother; 1984; 17(3):218-20. PubMed ID: 6236877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of medroxyprogesterone acetate upon PHA, Con A and PWM stimulated lymphocytes and on E-rosette function.
    Corsini G; Puppo F
    J Immunopharmacol; 1982-1983; 4(3):247-53. PubMed ID: 6223956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of antiestrogen and progestin on immune functions in breast cancer patients.
    Scambia G; Panici PB; Maccio A; Castelli P; Serri F; Mantovani G; Massidda B; Iacobelli S; Del Giacco S; Mancuso S
    Cancer; 1988 Jun; 61(11):2214-8. PubMed ID: 2966668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of antitumoral activity of medroxyprogesterone acetate for endometrial cancer.
    Fujimoto J; Fujita H; Hosoda S; Okada H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1836-40. PubMed ID: 2531782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No effect of high-dose medroxyprogesterone acetate on the frequency of sister chromatid exchange in lymphocytes of cancer patients.
    Becher R
    Oncology; 1988; 45(1):57-60. PubMed ID: 2963244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of medroxyprogesterone acetate on side effects of CAP therapy in gynecological malignant tumors].
    Yanagawa Y; Okazaki T; Okamura S; Ueki M; Sugimoto O
    Gan To Kagaku Ryoho; 1989 Jul; 16(7):2393-8. PubMed ID: 2526618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grwoth hormone, prolactin, and cortisol in dogs developing mammary nodules and an acromegaly-like appearance during treatment with medroxyprogesterone acetate.
    Concannon P; Altszuler N; Hampshire J; Butler WR; Hansel W
    Endocrinology; 1980 Apr; 106(4):1173-7. PubMed ID: 6444575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
    Mallmann P; Dietrich K; Krebs D
    Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
    de Greef WJ; Dullaart J; Zeilmaker GH
    J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
    Husslein P; Egarter C; Eppel W; Salzer H; Spona J
    Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tumour promoter phorbol myristate acetate on mouse lymphocytes: selective inhibition of B cell activation by mitogens and antigens.
    Hawrylowicz CM; Klaus GG
    Immunology; 1984 Feb; 51(2):327-32. PubMed ID: 6607211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of lymphocyte transformation after aspirin ingestion.
    Crout JE; Hepburn B; Ritts RE
    N Engl J Med; 1975 Jan; 292(5):221-3. PubMed ID: 1078593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transforming growth factor gene expression in human endometrial adenocarcinoma cells: regulation by progestins.
    Gong Y; Anzai Y; Murphy LC; Ballejo G; Holinka CF; Gurpide E; Murphy LJ
    Cancer Res; 1991 Oct; 51(20):5476-81. PubMed ID: 1833051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medroxyprogesterone acetate enhances spontaneous mammary tumorigenesis and uterine adenomyosis in mice.
    Nagasawa H; Aoki M; Sakagami N; Ishida M
    Breast Cancer Res Treat; 1988 Sep; 12(1):59-66. PubMed ID: 2973820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
    Guerin JF; Rollet J
    Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progesterone receptors in endometrial carcinoma and their response to medroxyprogesterone acetate].
    Feng YJ; Zhang XY
    Zhonghua Fu Chan Ke Za Zhi; 1989 May; 24(3):153-5, 189. PubMed ID: 2530067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.
    Laatikainen T; Nieminen U; Adlercreutz H
    Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of aromatase activity in human endometrial stromal cells by steroids, tamoxifen and RU 486.
    Tseng L; Mazella J; Sun B
    Endocrinology; 1986 Apr; 118(4):1312-8. PubMed ID: 2936597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes.
    Kontula K; Paavonen T; Luukkainen T; Andersson LC
    Biochem Pharmacol; 1983 May; 32(9):1511-8. PubMed ID: 6222739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone receptors and ventilatory stimulation by progestin.
    Brodeur P; Mockus M; McCullough R; Moore LG
    J Appl Physiol (1985); 1986 Feb; 60(2):590-5. PubMed ID: 2936712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.